105 results about "Follicular stimulating hormone" patented technology

The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (αFSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (βFSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.

A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

The present invention relates to a system for assessing ovarian reserve functions in subjects. The system for assessing the ovarian reserve functions of the subjects comprises a data acquisition module used for obtaining data of a subject's age, an anti-Mullerian hormone (AMH) level, a follicle stimulating hormone (FSH) level and antral follicle counting (AFC); and a module for calculating the ovarian reserve functions used for calculating information obtained in the data acquisition module to calculate a probability (p) of subject's ovarian hyporesponsiveness. Further, a relationship betweenthe predicted ovarian hyporesponsiveness probability and a medicine dose of an ovulation-promoting medicine is predicted to divide populations into four groups in order to group closes ovarian responsiveness into one group.

The invention provides a method for preparing follicle-stimulating hormone FSH. The method comprises the steps as follows: (A) a raw material containing the FSH is contacted with an antibody, wherein, the raw material contains luteinizing hormone LH and / or chorionic gonadotropin CG as impurities, and the antibody is an antibody which specifically combines the LH and / or the CG but not crossly react with the FSH basically, thereby making the antibody form an antigen-antibody compound with the LH and / or the CG; (B) the formed antigen-antibody compound is removed from the raw material, thereby obtaining purified FSH. The invention also provides a method for preparing a drug composition containing the FSH.

The invention relates to a system for predicting the number of oocytes obtained during ovarian stimulation of an object receiving a standard GnRH antagonist solution for ovulation induction. The system comprises a data acquisition module used for obtaining data of the anti-mullerian hormone (AMH) level, basal follicle stimulating hormone (FSH) level and antrum follicle count (AFC) of the object and a module used for predicting the number of the oocytes obtained during the ovarian stimulation and calculating the information obtained in the data acquisition module to calculate the number of theoocytes (NROs) obtained by the object.

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

The present invention relates to compounds Formula I (I) that are modulators of the follicle stimulating hormone (FSH) receptor and are useful in the treatment of infertility and related disorders.

The invention discloses a urinary follicle stimulating hormone with a purity of no more than 95w / w%; and the impurity content is not more than 5w / w%. Simultaneously, the invention discloses a preparation method for the urinary follicle stimulating hormone with high purity.

The present invention relates to a system for predicting the probability of poor ovarian response of a subject under an antagonist regimen, and a system for guiding the selection of a gonadotropin starting medication dose. The system for predicting the probability of poor ovarian response includes: a data acquisition module for acquiring the age, the anti-Mullerian hormone (AMH) level, the follicle stimulating hormone (FSH) level, the antralfollicle count (AFC) data of the subject; and a module for calculating the probability of poor ovarian response, which is used for calculating the information obtained in the data acquisition module to calculate the probability of poor ovarian response of the subject, and giving a starting dose recommendation for exogenous gonadotropin (Gn) based on thepredicted probability of poor ovarian response.

The present invention relates to the field of pharmaceutical preparations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and mixtures of FSH and LH and methods for the production of these preparations. The present invention also provides liquid or lyophilized formulations of FSH, or LH, or FSH and LH, which contain a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.

The invention relates to a urethrotropin freeze-dried powder injection and a preparation method thereof. In every 1 mg freeze-dried powder injection: the active ingredient is 60-200 units based on the titer of follicle-stimulating hormone, and the auxiliary materials are L-arginine, The composition of mannitol and phosphate buffer salt is 4-8:20-40:2.0-6.0 according to the weight ratio. The formula of the present invention prevents the urea gonadotropin from existing in the aqueous solution state for a long time in the preparation process, reduces the freeze-drying time, and increases the stability of the urea gonadotropin freeze-dried powder injection.

The invention discloses the FSH receptor special bonding area polypeptide, expression vector, the preparation method and their pharmaceutical application. Wherein, the polypeptide has amino acid sequence shown as SEQ ID No.2, SEQ ID No.4 or SEQ ID No.6, and can restrain spermatogenesis safely without effect to androgen and as the gene vaccine for male contraceptive.

The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU / ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.

The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.

The present invention provides methods of producing biologically active recombinant eFSH analogs and methods of increasing reproduction in mammals, particularly equine, using recombinant eFSH analogs. Also provided are methods of producing biologically active single chain recombinant eFSH. The recombinant eFSH analogs of the present invention increase superovulation, follicular development, embryo development, and reproductive efficiency in horses, cattle and other ungulates.

The invention discloses an application of adipose tissue-derived stromal cells in treating premature ovarian failure, and belongs to the technical field of a biological medicine. Adipose tissue-derived stromal cells and its excreted cell factors, and other components at a certain ratio are applied to form adipose tissue-derived stromal cells; then the adipose tissue-derived stromal cells are prepared to be injection fluid and a drug patch; the injection fluid is injected to the zone where a focus locates through a local target injection method, and then the patch is pasted to a patient's navel; through an electromagnetic impulse generator, a drug is intermittently stimulated, and the secretion of follicle-stimulating hormone is promoted, ovary endometrium can be effectively repaired, the functional ovulation is promoted, and premature ovarian failure is effectively treated. In short, the application has the advantages of being safe and effective, higher in controllability and strong inpracticability.

The invention provides a Chinese herbal compound for treating the pubertal polycystic ovary syndrome. The Chinese herbal compound is prepared from, by weight, 30-35 parts of radix astragali, 20-25 parts of American ginseng, 15-20 parts of Radix Salviae Miltiorrhizae,, 15-20 parts of hawthorn, 15-20 parts of poria cocos, 20-25 parts of bighead atractylodes rhizome and 15-20 parts of tangerine peel. The pubertal polycystic ovary syndrome (PCOS) is treated through the method of tonifying qi and spleens, reducing phlegm, activating blood and regulating constitution; compared with other traditional Chinese medicine research, the Chinese herbal compound can reduce levels of luteinizing hormone (LH), luteinizing hormone / follicle-stimulating hormone (LH / FSH), testosterone (T) and androstenedione (AND) in serum of patients and also can reduce the levels of total cholesterol (TC) and apolipoprotein B (APOB) in blood fat, and therefore the aims of regulating the menstrual cycle, improving hyperandrogenism and correcting dyslipidemia are achieved.

Method of early detection of risk of infertility and ovarian aging in and treatment of a human female who has not experienced infertility and is not otherwise indicated to have premature ovarian aging. A number of CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and a testing regimen is performed only when the determined number of CGG repeats on one of the FMR1 gene alleles is less than 26. The testing regimen includes periodically measuring serum level of a hormone related to fertility, such as Anti-Müllerian Hormone, Follicle Stimulating Hormone and / or estradiol over a period of about three to eight years and, after each measurement, determining if the measured serum level is less than a set confidence interval for a human female of the same age of the female. If so, the human female is treated for premature ovarian aging.

The present invention relates to a diagnostic device for measuring the ratio of similar structural proteins among the proteins secreted in a liquid test sample taken from diagnosis subject. In further detail, the test device according to the present invention comprises detection marker-antibody conjugate recognizing the same site on two or more similar structural proteins and a detection zone in which antibody specifically recognizes each of said proteins via formation of sandwich type complex, wherein said antibodies form a set, and the present Invention relates to a diagnostic device for early diagnosis of polycystic ovary syndrome, abnormal pregnancy, prostatic carcinoma etc. based on determination of the ratio of follicle stimulating hormone and luteinizing hormone in case of polycystic ovary syndrome, the ratio between hCG isomers in case of abnormal pregnancy, and the ratio of prostate-specific antigens (PSA) in case of prostatic carcinoma.

The present invention relates to a method for mass-production of human follicle stimulating hormone, more precisely, to an expression vector containing human follicle stimulating hormone gene, a transformant transfected with the expression vector and a method for mass-production of human follicle stimulating hormone by using the same. Human follicle stimulating hormone can be produced largely by using an expression vector and a transformant of the present invention. Therefore the expression vector and the transformant of the present invention can be effectively used for the treatment of infertility.

The invention provides a veterinary follicle-stimulating hormone analogue and a preparation method thereof. A connecting sequence is designed according to length, foldability, hydrophobicity and charge effect of a connecting sequence between an alpha peptide chain and a beta peptide chain, the corresponding nucleotide sequence of the connecting sequence is any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:20, and respective expression quantity and biological activity are compared by virtue of the study. A fused protein of the prepared veterinary follicle-stimulating hormone analogue is similar to the known fused protein in term of biological functions, the expression quantity of multiple fused proteins is obviously increased, the veterinary follicle-stimulating hormone analogue can be used for replacing natural ovarian-stimulating hormone, has great commercial value and is worthy of wide-range popularization.